PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 215/56, 215/36, 215/22, A61K 31/47 — A1

(11) International Publication Number: **WO 00/03992**

(43) International Publication Date: 27 January 2000 (27.01.00)

(21) International Application Number: PCT/SE99/01271

(22) International Filing Date: 14 July 1999 (14.07.99)

(30) Priority Data:
9802550-5 15 July 1998 (15.07.98) SE

(71) Applicant: ACTIVE BIOTECH AB [SE/SE]; P.O. Box 724, S-220 07 Lund (SE).

(72) Inventors: BJÖRK, Anders; Svalvägen 9, S-237 36 Bjärred (SE). JÖNSSON, Stig; Sofiaparken 2, S-222 41 Lund (SE). FEX, Tomas; Harpasset 1, S-226 52 Lund (SE). HEDLUND, Gunnar; Gullregnsvägen 131 E, S-224 56 Lund (SE).

(74) Agents: BERGVALL EFTRING, Stina, Lena et al.; Dr. Ludwig Brann Patentbyrå AB, P.O. Box 17192, S-104 62 Stockholm (SE).


(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Burasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: QUINOLINE DERIVATIVES

(57) Abstract

The invention is related to compounds of general formula (I) wherein R is Me, Et, n-Pr, iso-Pr, n-Bu, iso-Bu, sec.-Bu or allyl; R' is hydrogen, Me, MeO, fluoro, chloro, bromo, CF_3, or OCH_xF_y; R'' is hydrogen or fluoro, with the proviso that R'' is fluoro when R' is fluoro; and further when R' and R'' are both hydrogen, R is not Me; R_4 is selected from hydrogen and pharmaceutically acceptable inorganic and organic cations; R_5 is selected from MeS, EtS, n-PrS, iso-PrS, MeSO, EtSO, $MeSO_2$ and $EtSO_2$; wherein x=0-2, y=1-3 with the proviso that x+y=3; and Me is methyl, Et is ethyl, Pr is propyl and Bu is butyl; and any tautomer, optical isomer and racemate thereof. The invention also relates to pharmaceutical compositions containing a compound of general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering of a compound having formula (I) to said mammal.



(I)